Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Apply
Ziftomenib
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step